Entries by Melanie Piontek

ARTES and Burnet Institute publish data on production and immunogenicity of malaria transmission-blocking vaccine candidates

ARTES Biotech­nol­o­gy and Bur­net Insti­tute recent­ly pub­lished data on the effi­cient pro­duc­tion of malar­ia vac­cine can­di­dates using virus-like par­ti­cles (VLP) pre­sent­ing malar­ia trans­mis­sion-stage anti­gens, which were capa­ble of induc­ing trans­mis­sion-block­ing anti­bod­ies.

ARTES attends BioEurope Spring 2019

Meet us at the Bio-Europe Spring 2018 tak­ing place in Vien­na, Aus­tria March 25 ‑27. Volk­er Jen­zelews­ki, Direc­tor Tech­nol­o­gy at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­ma­ceu­ti­cal and vac­cine prod­ucts.

ARTES and Minapharm joint forces

ARTES Biotech­nol­o­gy GmbH, Ger­many, and Minapharm Phar­ma­ceu­ti­cals and Chem­i­cal Indus­tries S.A.E., Egypt, joint­ly announced today the for­ma­tion of a new strate­gic busi­ness pact, offer­ing pack­et solu­tion for bio­phar­ma­ceu­ti­cal process­es .   Aim of this new strate­gic busi­ness coop­er­a­tion is to joint­ly out-license com­bi­na­tions of ARTES’ and Minapharm’s respec­tive pro­pri­etary tech­nolo­gies and prod­ucts to third par­ties […]